Evidence map›Paper›PMID 21191423›Full record

ReviewNature reviews. Genetics2011

RNA sequencing: advances, challenges and opportunities.

Fatih Ozsolak, Patrice M Milos

Abstract readReview
In one paragraph

Review in Nature reviews. Genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,019 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,019citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1,019 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

959 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fatih OzsolakHelicos BioSciences Corporation, One Kendall Square, Cambridge, Massachusetts 02139, USA. fozsolak@helicosbio.com
Patrice M Milos

Funding

Attomole-Level High-Throughput GenomicsR44HG005279 · NHGRI · SEQLL, LLC · PI KAPRANOV, PHILIPP · 2010 to 2012
$1.6M
True Direct Single Molecule RNA SequencingR01HG005230 · NHGRI · SEQLL, LLC · PI MILOS, PATRICE M · 2010 to 2012
$1.6M
NHGRI NIH HHS R01 HG005230NHGRI NIH HHS R44 HG005279
6 · The paper itself

Abstract

In the few years since its initial application, massively parallel cDNA sequencing, or RNA-seq, has allowed many advances in the characterization and quantification of transcriptomes. Recently, several developments in RNA-seq methods have provided an even more complete characterization of RNA transcripts. These developments include improvements in transcription start site mapping, strand-specific measurements, gene fusion detection, small RNA characterization and detection of alternative splicing events. Ongoing developments promise further advances in the application of RNA-seq, particularly direct RNA sequencing and approaches that allow RNA quantification from very small amounts of cellular materials.

Indexed as

Alternative SplicingAnimalsHumansRNASequence Analysis, RNATranscription, GeneticRNA

Identifiers

PMID21191423
PMCPMC3031867

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.